Skip directly to content

Minimize RSR Award Detail

Research Spending & Results

Award Detail

Doing Business As Name:University of Minnesota-Twin Cities
  • Allison Hubel
  • (612) 626-4451
Award Date:11/25/2019
Estimated Total Award Amount: $ 50,000
Funds Obligated to Date: $ 50,000
  • FY 2020=$50,000
Start Date:12/01/2019
End Date:05/31/2021
Transaction Type:Grant
Awarding Agency Code:4900
Funding Agency Code:4900
CFDA Number:47.041
Primary Program Source:040100 NSF RESEARCH & RELATED ACTIVIT
Award Title or Description:I-Corps: Naturally inspired approach to preserving cellular therapies
Federal Award ID Number:1951443
DUNS ID:555917996
Parent DUNS ID:117178941
Program Officer:
  • Ruth Shuman
  • (703) 292-2160

Awardee Location

Street:200 OAK ST SE
Awardee Cong. District:05

Primary Place of Performance

Organization Name:University of Minnesota-Twin Cities
Street:111 Church St SE
Cong. District:05

Abstract at Time of Award

The broader impact/commercial potential of this I-Corps project is to provide a new platform for the cryopreservation of cellular therapies. This technology will allow for improved preservation of cells through the development of cell-type specific cryoprotective solutions and protocols that deliver high survival and function of cells after freezing and thawing. The cell therapy industry is a rapidly growing market that is expected to reach $8.21 billion by 2025. The proposed project will impact the cell therapy industry by improving quality of cells after freezing and thawing, extending the shelf life of these cells from hours or days to months or years, and alleviating processing bottlenecks associated with current preservation methods. This technology can be adapted for a variety of cell types, which may be administered to patients as cell therapies, used for research applications, or stored in biobanks. This I-Corps Teams project builds upon prior research in the development of cryoprotective solutions and protocols for a variety of cell types. The technology utilizes algorithm-driven optimization to create novel, nontoxic cryoprotective solutions inspired by how organisms survive freezing in nature. Proof-of-concept has been demonstrated with a cryoprotective solution and protocol optimized for the preservation of mesenchymal stem cells, which is currently undergoing beta testing at 8 sites. Additional technologies for other cell types are in progress. Development of this technology for specific markets requires a thorough understanding of customer needs. This I-Corps team project is aimed at identifying customer needs through customer discovery interviews, which will inform the development of new products in our pipeline to meet these specific needs. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

For specific questions or comments about this information including the NSF Project Outcomes Report, contact us.